A possible chemotherapy for small cell carcinoma of the prostate?

Small cell carcinoma of the prostate or SCCP is a rare, aggressive, and treatment-refractory form of prostate cancer. No good form of treatment is yet known for this disease, and median survival from initial diagnosis is less than 2 years. However, new data from a mouse model of SCCP has suggested that combining two well understood and widely available chemotherapeutic agents may have a significant clinical effect on patients with SCCP.

Tung et al. used a mouse model of SCCP to show that:

  • Irinotecan (at 20 mg/kg/day on days 1-3 and 8-10) completely arrested growth of human SCCP implants (xenografts) in their mice, with a small reduction in tumor volume and only minor weight loss (7 percent) of the mice.
  • Irinotecan (at 12 mg/kg, also on days 1-3 and 8-10) + cisplatinum (at 2.5 mg/kg/day on days 1 and 8) had a similar effect, but with less weight loss among the mice.

The authors conclude, cautiously, that, “irinotecan could be useful for therapy of refractory prostatic SCC, in particular in combination with cisplatin[um].” [Bold italic type added for emphasis.]

The “New” Prostate Cancer InfoLink regularly points out that data from animal models and subsequent clinical effectiveness in man are two very different things. However, given the complete lack of any clinically effective forms of treatment for SCCP, any form of good news offers potential hope for patients with such a diagnosis. We suspect that we may see a small trial of irinotecan — with or without cisplatinum —  in treatment of men with SCCP in the not too distant future. As yet, however, there are no such trials posted on ClinicalTrials.gov.

3 Responses

  1. I am suffering from a small cell prostate cancer. I am a patient at Herlev University Hospital in Copenhagen. I would be interested in participating in a trial with irinotecan.

    Chr. Bast

  2. Any news on trials for this drug??

  3. Kate:

    I did a quick search of the ClinicalTrials.gov web site and was unable to identify any ongoing or recent clinical trial of irinotecan in small cell cancer of the prostate.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: